Alliancebernstein L.P. Acquires 34,397 Shares of Lantheus Holdings, Inc. $LNTH

Key Points

• Alliancebernstein L.P. increased its stake in Lantheus Holdings, Inc. by 24%, now owning 177,850 shares valued at approximately $17.36 million.
• Lantheus reported earnings of $1.57 per share for the last quarter, missing analyst expectations, with revenue of $378.05 million, down 4.1% year-over-year.
• Insiders, including Farallon Partners and Rajiv A. Patel, sold approximately 6.81 million shares of Lantheus stock valued at over $382 million in recent months.

Alliancebernstein L.P. increased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 24.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 177,850 shares of the medical equipment provider's stock after acquiring an additional 34,397 shares during the quarter. Alliancebernstein L.P. owned approximately 0.26% of Lantheus worth $17,358,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of LNTH. TD Asset Management Inc lifted its holdings in Lantheus by 1,028.0% in the 1st quarter. TD Asset Management Inc now owns 682,614 shares of the medical equipment provider's stock worth $66,623,000 after buying an additional 622,100 shares during the period. Nuveen LLC purchased a new stake in Lantheus in the 1st quarter worth approximately $55,941,000. Epoch Investment Partners Inc. purchased a new stake in Lantheus in the 1st quarter worth approximately $35,548,000. Assenagon Asset Management S.A. lifted its holdings in Lantheus by 1,196.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider's stock worth $32,817,000 after buying an additional 310,301 shares during the period. Finally, Mackenzie Financial Corp lifted its holdings in Lantheus by 129.2% in the 1st quarter. Mackenzie Financial Corp now owns 497,437 shares of the medical equipment provider's stock worth $48,550,000 after buying an additional 280,381 shares during the period. Hedge funds and other institutional investors own 99.06% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on LNTH shares. William Blair reiterated a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. JMP Securities dropped their price objective on Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a report on Thursday, August 7th. Truist Financial set a $63.00 price objective on Lantheus and gave the stock a "hold" rating in a report on Monday, August 11th. Mizuho lowered their target price on Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th. Finally, B. Riley lowered their target price on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research note on Monday, June 23rd. Four research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $91.60.

Insiders Place Their Bets

In other Lantheus news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of Lantheus stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Rajiv A. Patel sold 3,365,000 shares of Lantheus stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares of the company's stock, valued at $195,246,296.05. The trade was a 49.18% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,812,000 shares of company stock valued at $382,427,380 in the last quarter. 1.50% of the stock is owned by company insiders.

Lantheus Stock Down 3.7%

Shares of LNTH traded down $2.05 on Friday, reaching $52.94. The stock had a trading volume of 842,370 shares, compared to its average volume of 1,507,125. The company has a 50-day simple moving average of $63.98 and a 200-day simple moving average of $81.27. The firm has a market capitalization of $3.60 billion, a price-to-earnings ratio of 14.08 and a beta of 0.15. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $118.21. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). The company had revenue of $378.05 million for the quarter, compared to analysts' expectations of $389.69 million. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The firm's quarterly revenue was down 4.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.80 EPS. Sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.